Erasca
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 300, San Diego, ...Phone Number
(858) 465-6511Website
www.erasca.comRevenue
$26.6 MillionStock Symbol
ERASIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Erasca
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately 5.5 million new patients diagnosed globally per year. We believe that to effectively shut down a pathway that signals as promiscuously as RAS/MAPK, a holistic approach must be taken to target not just individual nodes, but multiple nodes and cooperative mechanisms in parallel. Consequently, we are pursuing three therapeutic strategies that may be used in combination to comprehensively, and perhaps synergistically, shut down the RAS/MAPK pathway.Explore more
Erasca Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Erasca your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Erasca has new funding data
Product Launch: Get notified when Erasca launches new products
Erasca, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Erasca had a recent Job posting/layoffs
Check out if Erasca is spiking on competitors!
Check if Erasca has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Erasca
Earning: See what the market has to say on Erasca recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Erasca as Masked Content
Find 3 more new buyers
Compare Similar Companies to Erasca
Compare insights from companies similar to Erasca, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Erasca is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Erasca is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Erasca.
Erasca financials insights
Gather financial insights about Erasca, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$64M
2020
Series B
$200M
2021
Share Placement
$300M
Erasca Tech Stack
A closer look at the technologies used by Erasca
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Open Position
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Partnership, Medical Research, Pharmaceuticals
Erasca News & Media
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015)....Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead candidate, ERAS-0015, in KRAS G12X lung and pancreatic cancers. The company is accelerating development, having already initiated monotherapy […]Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.Erasca to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participat
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Erasca
Sign Up For FreeTo access detailed company insights
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately... Read More
